Literature DB >> 15544356

Real-time measurement of in vitro peptide binding to soluble HLA-A*0201 by fluorescence polarization.

Rico Buchli1, Rodney S VanGundy, Heather D Hickman-Miller, Christopher F Giberson, Wilfried Bardet, William H Hildebrand.   

Abstract

Measuring the interaction of class I human leukocyte antigens (HLA) and their peptide epitopes acts as a guide for the development of vaccines, diagnostics, and immune-based therapies. Here, we report the development of a sensitive biochemical assay that relies upon fluorescence polarization to indicate peptide interactions with recombinant soluble HLA proteins. It is a cell- and radioisotope-free assay that has the advantage of allowing the direct, real-time measurement of the ratio between free and bound peptide ligand in solution without separation steps. Peptide/HLA assay parameters were established using several HLA A*0201-specific fluorescein isothiocyanate-labeled peptides. Optimal loading of synthetic peptides into fully assembled soluble HLA-A*0201 complexes was enabled by thermal destabilization at 53 degrees C for 15 min, demonstrating that efficient peptide exchange does not require the removal of endogenous peptides from the reaction environment. An optimal ratio of three beta-2 microglobulin molecules per single HLA heavy chain was determined to maximize peptide binding. Kinetic binding studies indicate that soluble HLA-A*0201/peptide interactions are characterized by a range of moderate k(on) values (1 x 10(4) to 8.7 x 10(4) M(-1) s(-1)) and slow k(off) values (1.9 x 10(-4) to 4.3 x 10(-4) s(-1)), consistent with parameters for native HLA molecules. Testing of the A*0201-specific peptides with 48 additional class I molecules demonstrates that the unique peptide binding behavior of individual HLA molecules is maintained in the assay. This assay therefore represents a versatile tool for characterizing the binding of peptide epitopes during the development of class I HLA-based vaccines and immune therapies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15544356     DOI: 10.1021/bi048580q

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  16 in total

1.  Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7.

Authors:  Arnold H Bakker; Rieuwert Hoppes; Carsten Linnemann; Mireille Toebes; Boris Rodenko; Celia R Berkers; Sine Reker Hadrup; Wim J E van Esch; Mirjam H M Heemskerk; Huib Ovaa; Ton N M Schumacher
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

2.  Real-time, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay.

Authors:  Mikkel Harndahl; Michael Rasmussen; Gustav Roder; Søren Buus
Journal:  J Immunol Methods       Date:  2010-10-31       Impact factor: 2.303

3.  T-cell tolerance for variability in an HLA class I-presented influenza A virus epitope.

Authors:  Angela Wahl; William McCoy; Fredda Schafer; Wilfried Bardet; Rico Buchli; Daved H Fremont; William H Hildebrand
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

4.  Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture.

Authors:  John Sidney; Scott Southwood; Carrie Moore; Carla Oseroff; Clemencia Pinilla; Howard M Grey; Alessandro Sette
Journal:  Curr Protoc Immunol       Date:  2013-02

5.  Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity.

Authors:  Michael A Norcross; Shen Luo; Li Lu; Michael T Boyne; Mary Gomarteli; Aaron D Rennels; Janet Woodcock; David H Margulies; Curtis McMurtrey; Stephen Vernon; William H Hildebrand; Rico Buchli
Journal:  AIDS       Date:  2012-07-17       Impact factor: 4.177

6.  Human Leukocyte Antigen-Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer.

Authors:  Andrea M Patterson; Saghar Kaabinejadian; Curtis P McMurtrey; Wilfried Bardet; Ken W Jackson; Rosemary E Zuna; Sanam Husain; Gregory P Adams; Glen MacDonald; Rachelle L Dillon; Harold Ames; Rico Buchli; Oriana E Hawkins; Jon A Weidanz; William H Hildebrand
Journal:  Mol Cancer Ther       Date:  2015-12-30       Impact factor: 6.261

7.  Human herpesvirus 7 U21 tetramerizes to associate with class I major histocompatibility complex molecules.

Authors:  Nathan A May; Qiuhong Wang; Andrea Balbo; Sheryl L Konrad; Rico Buchli; William H Hildebrand; Peter Schuck; Amy W Hudson
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

8.  Novel cellular microarray assay for profiling T-cell peptide antigen specificities.

Authors:  C Yue; M Oelke; M E Paulaitis; J P Schneck
Journal:  J Proteome Res       Date:  2010-10-04       Impact factor: 4.466

9.  Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells.

Authors:  Jane C Yaciuk; Matthew Skaley; Wilfried Bardet; Fredda Schafer; Danijela Mojsilovic; Steven Cate; Christopher J Stewart; Curtis McMurtrey; Kenneth W Jackson; Rico Buchli; Alex Olvera; Samandhy Cedeño; Montserrat Plana; Beatriz Mothe; Christian Brander; John T West; William H Hildebrand
Journal:  J Virol       Date:  2014-08-27       Impact factor: 5.103

10.  HLA class I molecules consistently present internal influenza epitopes.

Authors:  Angela Wahl; Fredda Schafer; Wilfried Bardet; Rico Buchli; Gillian M Air; William H Hildebrand
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.